Gain Therapeutics (NASDAQ:GANX) Raised to Strong-Buy at Roth Capital

Gain Therapeutics (NASDAQ:GANX) was upgraded by equities researchers at Roth Capital to a “strong-buy” rating in a report issued on Thursday,Zacks.com reports.

A number of other equities analysts have also commented on GANX. Roth Mkm started coverage on shares of Gain Therapeutics in a research report on Friday. They set a “buy” rating and a $7.00 price target on the stock. HC Wainwright reaffirmed a “buy” rating and set a $8.00 target price on shares of Gain Therapeutics in a report on Monday, November 25th. Oppenheimer reiterated an “outperform” rating and issued a $8.00 price target on shares of Gain Therapeutics in a research note on Wednesday, August 14th. Finally, Chardan Capital restated a “buy” rating and set a $6.00 price objective on shares of Gain Therapeutics in a research note on Friday, August 9th. Four analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat, the stock currently has an average rating of “Buy” and a consensus price target of $7.25.

Gain Therapeutics Stock Performance

Shares of NASDAQ GANX opened at $1.79 on Thursday. Gain Therapeutics has a one year low of $0.89 and a one year high of $5.33. The company has a debt-to-equity ratio of 0.04, a current ratio of 2.99 and a quick ratio of 2.99. The firm has a market cap of $47.47 million, a price-to-earnings ratio of -1.63 and a beta of 0.21. The stock’s fifty day moving average price is $2.09 and its two-hundred day moving average price is $1.68.

Institutional Trading of Gain Therapeutics

Institutional investors and hedge funds have recently made changes to their positions in the company. Warberg Asset Management LLC acquired a new position in Gain Therapeutics during the second quarter valued at approximately $66,000. Renaissance Technologies LLC raised its holdings in shares of Gain Therapeutics by 154.2% during the 2nd quarter. Renaissance Technologies LLC now owns 118,700 shares of the company’s stock worth $152,000 after buying an additional 72,000 shares in the last quarter. Hohimer Wealth Management LLC bought a new stake in shares of Gain Therapeutics during the 2nd quarter worth $422,000. Finally, Geode Capital Management LLC boosted its stake in Gain Therapeutics by 48.0% in the third quarter. Geode Capital Management LLC now owns 271,972 shares of the company’s stock valued at $484,000 after buying an additional 88,236 shares in the last quarter. Institutional investors own 11.97% of the company’s stock.

Gain Therapeutics Company Profile

Gain Therapeutics, Inc, a biotechnology company, develops novel small molecule therapeutics to treat diseases across various therapeutic areas. Its drug discovery platform Magellan discovers novel allosteric binding sites in a disease; identifies proprietary small molecules that bind these sites to modulate protein function; and treats the underlying cause of the disease.